Experience

Symbiotix, LLC
• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee
• VP - Medical Director

  • Jul 2019 - Present


Phase II US

• Chief Scientific Officer

  • Aug 2017 - Jul 2019

  Lead all medical communications activities for oncology and hematology accounts. Added a new Global account and lead the medical communications related activities for a CAR-T therapy in NHL. Coordinate the day-to-day content management of an online educational platform for HCPs in lymphoma, working closely with the Steering Committee experts as well as the Scientific Societies partners. Launched and manage 3 additional online educational platforms for HCPs, in AML, MM and GvHD. Lead a medical writers team Show less



ONCOSULT Limited

• Advertising Services

• Director

  • Mar 2014 - Aug 2017

  Offered consulting services in medical affairs or marketing to pharmaceutical companies or medical communications agencies, in oncology and hematology. Served as Scientific Director for Phase II International (2016-17, London, UK) with scientific strategy responsibility, development of narratives, implementation of training programs for MSLs. Served as Medical Director oncology/hematology for Publicis Health (2014-16, London, UK) leading the medical communications team. Served as EU oncology/hematology expert for Digitas Health US and H4B (pitches, scientific platforms in NSCLC, BC, MM and ALL) Worked with Publicis Life Brands, Havas Medicom in BC and NSCLC. Designed and led advisory boards for pharma companies. Show less



ONCOSULT

• Advertising Services

• CEO

  • Sep 2002 - Dec 2013

  Consulting activities - Marketing Marketing plans, launch strategies, campaigns, build-up and management of advisory boards, MSLs training. - Medical Affairs Product and patients leaflets, Q&A, Conferences, Press dossiers and press releases, management of advisory boards. - PR - Fundraising Consulting activities - Marketing Marketing plans, launch strategies, campaigns, build-up and management of advisory boards, MSLs training. - Medical Affairs Product and patients leaflets, Q&A, Conferences, Press dossiers and press releases, management of advisory boards. - PR - Fundraising

• Free-lance Consultant in oncology / haematology

  • Sep 2000 - Aug 2002

  Medical Affairs and marketing Consultant in oncology and hematology Medical Affairs and marketing Consultant in oncology and hematology



Chiron Corporation

• United States
• Biotechnology
• 100 - 200 Employee

• Managing Director

  • Mar 1997 - Aug 2000

  Management of the French affiliate: Marketing, Medical,Sales, Regulatory, HR and Finances Management: 25 people (12 in 1997) Turnaround Cardioxane brand to achieve 800% growth in 3 years Profit jumped from -4 MFF to +5 MFF Obtained an "ATU" for interleukin-2 in HIV Management of the French affiliate: Marketing, Medical,Sales, Regulatory, HR and Finances Management: 25 people (12 in 1997) Turnaround Cardioxane brand to achieve 800% growth in 3 years Profit jumped from -4 MFF to +5 MFF Obtained an "ATU" for interleukin-2 in HIV



Gilead Sciences

• United States
• Biotechnology Research
• 700 & Above Employee

• Scientific Director

  • Sep 1996 - Mar 1997

  Development and implementation of the medico-marketing strategy of the 2 in-line products, DaunoXome and AmBisome. Development and implementation of the medico-marketing strategy of the 2 in-line products, DaunoXome and AmBisome.



Asta Medica France

• Oncology Business Unit Manager

  • Oct 1990 - Aug 1996

  Built up and managed of the new Oncology Business Unit with 3 departments: Medical, Marketing and Sales (24 people: 2 Medical Managers, 1 Product Manager, 2 Sales Managers, 16 Representatives, 1 Tender Business Manager, 2 Administrative Managers). Turnaround Holoxan brand to achieve 500% growth in 5 years Turnover of the BU x 3.5 Profitability of the BU x 4.5 MS changed from 6% to 16% Built up and managed of the new Oncology Business Unit with 3 departments: Medical, Marketing and Sales (24 people: 2 Medical Managers, 1 Product Manager, 2 Sales Managers, 16 Representatives, 1 Tender Business Manager, 2 Administrative Managers). Turnaround Holoxan brand to achieve 500% growth in 5 years Turnover of the BU x 3.5 Profitability of the BU x 4.5 MS changed from 6% to 16%



Schering-Plough Research Institute

• United States
• Pharmaceutical Manufacturing
• 400 - 500 Employee

• Interferon Product Manager

  • Sep 1988 - Oct 1990

  Led the marketing strategy in approved indications. Prepared the extension of approvals by initiating a national phase III in CML and the new IFM cooperative group in MM

• Interferon Specialist

  • Mar 1987 - Sep 1988

  Promotion of Introna in the hospitals located in Western France and in Paris.